Equivocal (HER2 IHC 2+) breast carcinomas: gene –protein assay testing reveals association between genetic heterogeneity, individual cell amplification status and potential treatment benefits

ConclusionNon ‐heterogeneous HER2 IHC 2+ tumours tend to be HER2‐amplified. Adding the percentage of cells with HER2>6 copies to the average HER2/CEP17 ratio may facilitate assessment of amplification status in ISH ‐equivocal cases. The proportion of cells with HER2/CEP17 ≥2.0 contributes information concerning the actual average HER2/CEP17 ratio, depending on tumour type.

Source: Histopathology - November 11, 2018 Category: Pathology Authors: Gyula Pekar, Ionna Kasselaki, Agnes Pekar ‐Lukacs, Csaba Dekany, Dan Hellberg, Tibor Tot Tags: Original Article Source Type: research